Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic

features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline

infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.
Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.

Pseudocholinesterase inhibitors have long been recognized as a potential treatment for the dystonic
features of Parkinson or pyramidal symptoms of antipsychotics. Following IV injection with saline
infusion, rapid metabolism by cholinesterases, especially in the liver limits a long half life. The
advantage is an obvious reduction of adverse drug reactions with less tissue-related accumulation of
the drug.